| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2083133 | Drug Discovery Today: Therapeutic Strategies | 2006 | 7 Pages |
Abstract
The 21st century continues to witness the threat of tuberculosis. Drug treatments are available, but multidrug-resistant strains are on the rise and the most widely used vaccine only protects against severe forms of childhood tuberculosis and fails to prevent the most prevalent form – pulmonary tuberculosis in adults. Several new vaccine candidates have recently been produced for clinical trial testing, including subunit and viable attenuated vaccines. Probably a combination of both will give the best results. To speed up clinical vaccine trials, biomarkers of protective immunity are urgently needed.
Section editors:Gary Woodnutt – CovX, San Diego, USAPaul-Henri Lambert – Centre of Vaccinology, University of Geneva, Switzerland
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Ali Nasser Eddine, Sven Baumann, Stefan H.E. Kaufmann,